About Index Trending news
Analyze
Top 50 Pricing

Cosmetics

10–100 Companies
Companies

Growing

85
Funding and Acquisitions

2016 Q3

3 + 1
Curators of Cosmetics
$24,000,000 Venture capital (Series B)
FinSMEs

Glossier Raises $24M in Series B Funding

Funding
Geektime.com

Procter & Gamble want 5 Israeli companies to help build Cincinnati corporate ties with startups

Funding Technology
$10,500,000 Venture capital (Series A)
BostInno

Fasten Raises $10M Series A to Up the Competition with Uber & Lyft

The Verge

Here's how the FDA wants drugs for women's sex drives to be developed

Health Diversity
€6,000,000 Venture capital (Series Undisclosed)
http://www.unquote.com

Otium Capital in €6m round for Oh My Cream | Unquote

Adweek

Brands Like Airbnb and P&G Express Interest in 'Saturday Morning' Social Justice Project

Advertising
Adweek

P&G's Marketing Chief Says It's Not Cutting Back on Facebook Ads, It's Targeting Better

Advertising
Business Insider

The FDA just approved another new drug that could save the US billions — but there's a catch

Xconomy

After New Data, FDA Bucks Advisory Panel, Approves Sarepta's Duchenne Drug

The Verge

FDA asked to restrict antibiotics on livestock

Xconomy

Julep CEO Disputes Attorney General’s Account of Settlement

TreeHugger.com

FDA ban on antibacterial soap is good, but what about everything else?

GeekWire

Julep CEO Jane Park blasts Washington State AG over characterization of lawsuit settlement, calls it ‘unethical’

Slashdot

FDA Bans 19 Chemicals Used In Antibacterial Soaps

The Verge

The FDA has banned antibacterial soap ingredients that were useless in the first place

AlleyWatch

How Startups Like Thinx and Glossier are Disrupting Out-of-Home Advertising

Slashdot

FDA Finds Flaws In Theranos' Zika Tests

The Verge , TechCrunch , WSJD , +2

Theranos hit by another setback as it withdraws request for Zika test approval

The Verge

FDA recommends testing all donated blood in the US for Zika virus

Xconomy

Duchenne Lessons: Advocates For Rare Spinal Disease Have Eyes on FDA